Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

NCT04596995 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT04596995
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04596995 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
Lead sponsor
UCB Biopharma SRL
Phase
Phase 3
Overall status
Terminated
Start date
January 6, 2021
Completion date
December 21, 2022
Enrollment
43 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

primary immune thrombocytopenia